Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors
To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs). Patients with SMBT between 2014 and 2018 and those with MB/APMT between 1988 and 2018 who underwent surg...
Gespeichert in:
| Veröffentlicht in: | In vivo (Athens) 2020-05, Vol.34 (3), p.1341-1346 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1346 |
|---|---|
| container_issue | 3 |
| container_start_page | 1341 |
| container_title | In vivo (Athens) |
| container_volume | 34 |
| creator | Hada, Taira Miyamoto, Morikazu Ishibashi, Hiroki Kawauchi, Haruka Soyama, Hiroaki Matsuura, Hiroko Sakamoto, Takahiro Kakimoto, Soichiro Aoyama, Tadashi Iwahashi, Hideki Suzuki, Rie Tsuda, Hitoshi Takano, Masashi |
| description | To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs).
Patients with SMBT between 2014 and 2018 and those with MB/APMT between 1988 and 2018 who underwent surgery at our Institution were identified. Pathological review was conducted using the 2014 World Health Organization criteria. Clinical features were compared retrospectively between SMBT and MB/APMT.
In total, 11 (12.9%) patients with SMBT and 74 (87.1%) patients with MB/APMT were included in our study. The diagnosis of six patients with SMBT and 73 patients with MB/APMT was not revised on review. SMBT was diagnosed at a younger age (p=0.04), was of smaller size (p |
| doi_str_mv | 10.21873/invivo.11911 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7279789</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2397677345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c453t-353cbea98af9a1bf2b64bc7f59d6a93f587de699ffb84260f847a236dc4279903</originalsourceid><addsrcrecordid>eNp1kTtPwzAUhS0EoqUwsqKMLCl-JLG9IJXyKFJRB4rEZjmOXYySuNhJpP57orZUMDDd4Z5z7rn6ALhEcIwRo-TG1p3t3BghjtARGCLKUUzThB-DIcQpi1mK3gfgLIRPCDMKIT4FA4JJr8BsCNSik97KOnrV3lWtsrVrQ3TnfKF9aWsdLdvK-RBNvI5mNjSudCurZFluontrjPa6biLTW6OXf83n4MTIMuiL_RyBt8eH5XQWzxdPz9PJPFZJSpqYpETlWnImDZcoNzjPklxRk_Iik5yYlNFCZ5wbk7MEZ9CwhEpMskIlmHIOyQjc7nLXbV7pQvXVvCzF2ttK-o1w0oq_m9p-iJXrBO39lPE-4Hof4N1Xq0MjKhuULktZ6_4zgQmnGaWkrzsC8U6qvAvBa3M4g6DYghE7MGILptdf_e52UP-QIN8ilY5o</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2397677345</pqid></control><display><type>article</type><title>Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Hada, Taira ; Miyamoto, Morikazu ; Ishibashi, Hiroki ; Kawauchi, Haruka ; Soyama, Hiroaki ; Matsuura, Hiroko ; Sakamoto, Takahiro ; Kakimoto, Soichiro ; Aoyama, Tadashi ; Iwahashi, Hideki ; Suzuki, Rie ; Tsuda, Hitoshi ; Takano, Masashi</creator><creatorcontrib>Hada, Taira ; Miyamoto, Morikazu ; Ishibashi, Hiroki ; Kawauchi, Haruka ; Soyama, Hiroaki ; Matsuura, Hiroko ; Sakamoto, Takahiro ; Kakimoto, Soichiro ; Aoyama, Tadashi ; Iwahashi, Hideki ; Suzuki, Rie ; Tsuda, Hitoshi ; Takano, Masashi</creatorcontrib><description>To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs).
Patients with SMBT between 2014 and 2018 and those with MB/APMT between 1988 and 2018 who underwent surgery at our Institution were identified. Pathological review was conducted using the 2014 World Health Organization criteria. Clinical features were compared retrospectively between SMBT and MB/APMT.
In total, 11 (12.9%) patients with SMBT and 74 (87.1%) patients with MB/APMT were included in our study. The diagnosis of six patients with SMBT and 73 patients with MB/APMT was not revised on review. SMBT was diagnosed at a younger age (p=0.04), was of smaller size (p<0.01) and bilateral (p=0.03), coexisted with endometriosis (p<0.01), and more frequently recurred than MB/APMT (p=0.04).
SMBT might be more aggressive than MB/APMT.</description><identifier>ISSN: 0258-851X</identifier><identifier>EISSN: 1791-7549</identifier><identifier>DOI: 10.21873/invivo.11911</identifier><identifier>PMID: 32354928</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Adult ; Diagnosis, Differential ; Female ; Humans ; Immunohistochemistry ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Neoplasms, Cystic, Mucinous, and Serous - diagnosis ; Ovarian Neoplasms - diagnosis ; Ovarian Neoplasms - pathology ; Tumor Burden ; Young Adult</subject><ispartof>In vivo (Athens), 2020-05, Vol.34 (3), p.1341-1346</ispartof><rights>Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright 2020, International Institute of Anticancer Research 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c453t-353cbea98af9a1bf2b64bc7f59d6a93f587de699ffb84260f847a236dc4279903</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279789/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279789/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32354928$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hada, Taira</creatorcontrib><creatorcontrib>Miyamoto, Morikazu</creatorcontrib><creatorcontrib>Ishibashi, Hiroki</creatorcontrib><creatorcontrib>Kawauchi, Haruka</creatorcontrib><creatorcontrib>Soyama, Hiroaki</creatorcontrib><creatorcontrib>Matsuura, Hiroko</creatorcontrib><creatorcontrib>Sakamoto, Takahiro</creatorcontrib><creatorcontrib>Kakimoto, Soichiro</creatorcontrib><creatorcontrib>Aoyama, Tadashi</creatorcontrib><creatorcontrib>Iwahashi, Hideki</creatorcontrib><creatorcontrib>Suzuki, Rie</creatorcontrib><creatorcontrib>Tsuda, Hitoshi</creatorcontrib><creatorcontrib>Takano, Masashi</creatorcontrib><title>Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors</title><title>In vivo (Athens)</title><addtitle>In Vivo</addtitle><description>To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs).
Patients with SMBT between 2014 and 2018 and those with MB/APMT between 1988 and 2018 who underwent surgery at our Institution were identified. Pathological review was conducted using the 2014 World Health Organization criteria. Clinical features were compared retrospectively between SMBT and MB/APMT.
In total, 11 (12.9%) patients with SMBT and 74 (87.1%) patients with MB/APMT were included in our study. The diagnosis of six patients with SMBT and 73 patients with MB/APMT was not revised on review. SMBT was diagnosed at a younger age (p=0.04), was of smaller size (p<0.01) and bilateral (p=0.03), coexisted with endometriosis (p<0.01), and more frequently recurred than MB/APMT (p=0.04).
SMBT might be more aggressive than MB/APMT.</description><subject>Adult</subject><subject>Diagnosis, Differential</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Neoplasms, Cystic, Mucinous, and Serous - diagnosis</subject><subject>Ovarian Neoplasms - diagnosis</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Tumor Burden</subject><subject>Young Adult</subject><issn>0258-851X</issn><issn>1791-7549</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kTtPwzAUhS0EoqUwsqKMLCl-JLG9IJXyKFJRB4rEZjmOXYySuNhJpP57orZUMDDd4Z5z7rn6ALhEcIwRo-TG1p3t3BghjtARGCLKUUzThB-DIcQpi1mK3gfgLIRPCDMKIT4FA4JJr8BsCNSik97KOnrV3lWtsrVrQ3TnfKF9aWsdLdvK-RBNvI5mNjSudCurZFluontrjPa6biLTW6OXf83n4MTIMuiL_RyBt8eH5XQWzxdPz9PJPFZJSpqYpETlWnImDZcoNzjPklxRk_Iik5yYlNFCZ5wbk7MEZ9CwhEpMskIlmHIOyQjc7nLXbV7pQvXVvCzF2ttK-o1w0oq_m9p-iJXrBO39lPE-4Hof4N1Xq0MjKhuULktZ6_4zgQmnGaWkrzsC8U6qvAvBa3M4g6DYghE7MGILptdf_e52UP-QIN8ilY5o</recordid><startdate>20200501</startdate><enddate>20200501</enddate><creator>Hada, Taira</creator><creator>Miyamoto, Morikazu</creator><creator>Ishibashi, Hiroki</creator><creator>Kawauchi, Haruka</creator><creator>Soyama, Hiroaki</creator><creator>Matsuura, Hiroko</creator><creator>Sakamoto, Takahiro</creator><creator>Kakimoto, Soichiro</creator><creator>Aoyama, Tadashi</creator><creator>Iwahashi, Hideki</creator><creator>Suzuki, Rie</creator><creator>Tsuda, Hitoshi</creator><creator>Takano, Masashi</creator><general>International Institute of Anticancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20200501</creationdate><title>Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors</title><author>Hada, Taira ; Miyamoto, Morikazu ; Ishibashi, Hiroki ; Kawauchi, Haruka ; Soyama, Hiroaki ; Matsuura, Hiroko ; Sakamoto, Takahiro ; Kakimoto, Soichiro ; Aoyama, Tadashi ; Iwahashi, Hideki ; Suzuki, Rie ; Tsuda, Hitoshi ; Takano, Masashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c453t-353cbea98af9a1bf2b64bc7f59d6a93f587de699ffb84260f847a236dc4279903</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adult</topic><topic>Diagnosis, Differential</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Neoplasms, Cystic, Mucinous, and Serous - diagnosis</topic><topic>Ovarian Neoplasms - diagnosis</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Tumor Burden</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hada, Taira</creatorcontrib><creatorcontrib>Miyamoto, Morikazu</creatorcontrib><creatorcontrib>Ishibashi, Hiroki</creatorcontrib><creatorcontrib>Kawauchi, Haruka</creatorcontrib><creatorcontrib>Soyama, Hiroaki</creatorcontrib><creatorcontrib>Matsuura, Hiroko</creatorcontrib><creatorcontrib>Sakamoto, Takahiro</creatorcontrib><creatorcontrib>Kakimoto, Soichiro</creatorcontrib><creatorcontrib>Aoyama, Tadashi</creatorcontrib><creatorcontrib>Iwahashi, Hideki</creatorcontrib><creatorcontrib>Suzuki, Rie</creatorcontrib><creatorcontrib>Tsuda, Hitoshi</creatorcontrib><creatorcontrib>Takano, Masashi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>In vivo (Athens)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hada, Taira</au><au>Miyamoto, Morikazu</au><au>Ishibashi, Hiroki</au><au>Kawauchi, Haruka</au><au>Soyama, Hiroaki</au><au>Matsuura, Hiroko</au><au>Sakamoto, Takahiro</au><au>Kakimoto, Soichiro</au><au>Aoyama, Tadashi</au><au>Iwahashi, Hideki</au><au>Suzuki, Rie</au><au>Tsuda, Hitoshi</au><au>Takano, Masashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors</atitle><jtitle>In vivo (Athens)</jtitle><addtitle>In Vivo</addtitle><date>2020-05-01</date><risdate>2020</risdate><volume>34</volume><issue>3</issue><spage>1341</spage><epage>1346</epage><pages>1341-1346</pages><issn>0258-851X</issn><eissn>1791-7549</eissn><abstract>To examine the clinicopathological features of ovarian seromucinous borderline tumors (SMBTs) and compare them with those of mucinous borderline/atypical proliferative mucinous tumors (MB/APMTs).
Patients with SMBT between 2014 and 2018 and those with MB/APMT between 1988 and 2018 who underwent surgery at our Institution were identified. Pathological review was conducted using the 2014 World Health Organization criteria. Clinical features were compared retrospectively between SMBT and MB/APMT.
In total, 11 (12.9%) patients with SMBT and 74 (87.1%) patients with MB/APMT were included in our study. The diagnosis of six patients with SMBT and 73 patients with MB/APMT was not revised on review. SMBT was diagnosed at a younger age (p=0.04), was of smaller size (p<0.01) and bilateral (p=0.03), coexisted with endometriosis (p<0.01), and more frequently recurred than MB/APMT (p=0.04).
SMBT might be more aggressive than MB/APMT.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>32354928</pmid><doi>10.21873/invivo.11911</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0258-851X |
| ispartof | In vivo (Athens), 2020-05, Vol.34 (3), p.1341-1346 |
| issn | 0258-851X 1791-7549 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7279789 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Diagnosis, Differential Female Humans Immunohistochemistry Middle Aged Neoplasm Grading Neoplasm Staging Neoplasms, Cystic, Mucinous, and Serous - diagnosis Ovarian Neoplasms - diagnosis Ovarian Neoplasms - pathology Tumor Burden Young Adult |
| title | Ovarian Seromucinous Borderline Tumors Are Histologically Different from Mucinous Borderline Tumors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A08%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20Seromucinous%20Borderline%20Tumors%20Are%20Histologically%20Different%20from%20Mucinous%20Borderline%20Tumors&rft.jtitle=In%20vivo%20(Athens)&rft.au=Hada,%20Taira&rft.date=2020-05-01&rft.volume=34&rft.issue=3&rft.spage=1341&rft.epage=1346&rft.pages=1341-1346&rft.issn=0258-851X&rft.eissn=1791-7549&rft_id=info:doi/10.21873/invivo.11911&rft_dat=%3Cproquest_pubme%3E2397677345%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2397677345&rft_id=info:pmid/32354928&rfr_iscdi=true |